APA (7th ed.) Citation

Black, S., Wilcock, G., Zavitz, K., Hendrix, S., & Swabb, E. (2008). Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment.

Chicago Style (17th ed.) Citation

Black, S., G. Wilcock, K. Zavitz, S. Hendrix, and E. Swabb. Efficacy and Safety of Tarenflurbil, a Selective a Beta 42-lowering Agent, in Alzheimer's Disease (AD): A Phase 2 Trial of Up to 24 Months of Treatment. 2008.

MLA (9th ed.) Citation

Black, S., et al. Efficacy and Safety of Tarenflurbil, a Selective a Beta 42-lowering Agent, in Alzheimer's Disease (AD): A Phase 2 Trial of Up to 24 Months of Treatment. 2008.